Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study

NCT00932607 is registered in ClinicalTrials.gov with HAL Allergy as lead sponsor.

NCT NCT00932607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00932607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study
Lead sponsor
HAL Allergy
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
Not reported
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

birch pollen allergy, seasonal rhinitis and/or rhinoconjunctivitis